Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.88 USD | -5.57% |
|
-11.11% | -88.41% |
05-14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
05-10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.41% | 106M | |
+15.82% | 121B | |
+20.35% | 113B | |
+17.47% | 26.02B | |
-25.31% | 19.39B | |
-19.51% | 15.91B | |
-19.67% | 15.09B | |
-46.87% | 15.06B | |
+62.55% | 14.93B | |
+6.34% | 13.85B |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating